Japan's MHLW Sets Size Requirements For Transdermal Patch Drug Listing
This article was originally published in PharmAsia News
Executive Summary
Regarding price listing for non-steroid anti-inflammation transdermal patches, Japan's Ministry of Health, Labor and Welfare ruled that unless there is a medical need requiring a special size, no new products beyond the current three patch sizes and two tape sizes will be listed. The sizes for patches are 7cm×10cm, 10cm×12cm, 14cm×20cm, the sizes for tapes are 7cm×10cm and 10cm ×14cm. MHLW hopes to reduce inventory burdens and clarify the specifications and requirements for drug approval and price listing. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.